CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Luye Pharma Group Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Luye Pharma Group Ltd
No.15 Chuangye Road, High-Tech Zone
Phone: +86 5356717618p:+86 5356717618 YANTAI, SDG  264003  China Ticker: 21862186

Business Summary
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer Dian BoLiu 57 6/8/2016 7/9/2003
Executive Vice Chairman of the Board Rong BingYang 57 3/30/2015 7/9/2003
Chief Financial Officer Yuan ChongLiu 59 1/1/2012 1/1/2012
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Luye Boston R&D LLC 19 PRESIDENTIAL WAY WOBURN MA
Luye Pharma (USA) Ltd. 502 CARNEGIE CTR STE 103 PRINCETON NJ United States

Business Names
Business Name
2186
AsiaPharm Group Ltd.
LUP
Luye Pharma Group Ltd

General Information
Number of Employees: 5,005 (As of 12/31/2022)
Outstanding Shares: 3,761,670,643 (As of 6/30/2023)
Shareholders: 581
Stock Exchange: HKG
Fax Number: +86 5356717718


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, March 27, 2024